FilingFirehose · custom report

SGMOQ — SANGAMO THERAPEUTICS, INC

SEC filings analysis · 6 filings reviewed (last 12 months) · generated 2026-07-27 14:35 UTC

Executive summary

Sangamo Therapeutics filed six 8-K forms over the past 12 months, with significant activity concentrated in mid-2026 including material agreements (Item 1.01), amendments to organizational documents (Item 3.01), costs associated with exit or disposal activities (Item 2.02), and creation of direct financial obligations (Item 2.05). The company reported a material definitive agreement on June 23, 2026, alongside employee termination costs (Item 2.02), suggesting a strategic pivot or restructuring. No ATM shelf offering or disclosed capital raises appear in the filing set, indicating reliance on existing cash or debt facilities.

Dilution risk 1/5

No equity issuances, share repurchase suspensions, warrant exercises, or stock-based compensation acceleration events are documented in the 8-K filings analyzed. The June 23, 2026 Item 1.01 (material agreement) and Item 2.05 (creation of direct financial obligations) do not indicate equity dilution; rather, they point to debt or contractual arrangements. Absent explicit disclosure of equity offerings or convertible instruments, dilution risk appears minimal based on these filings alone.

Six 8-K filings from May 2026 to April 2026 contain no Item 5.02 (Costs Associated with Exit or Disposal), Item 5.03 (Amendments to Articles), or Item 5.07 (Submission of Matters to a Vote) consistent with equity issuance.
No S-3 registration or ATM shelf capacity disclosed.
Item 2.05 filings (June 23, 2026; May 14, 2026) reference direct financial obligations but do not specify equity conversion features.

Notable filings (6)

2026-06-23 8-K	Material Definitive Agreement signed; employee termination costs and new financial obligations incurred. · filing Indicates a material business development, partnership, or acquisition with simultaneous workforce reduction (Item 2.02) and debt or liability creation (Item 2.05). Suggests operational restructuring or strategic realignment that may impact near-term profitability and headcount.
2026-07-01 8-K	Material Agreement or Financial Obligation (Item 4.01); amendments to organizational documents or bylaws (Item 3.01 buried under 8.01). · filing Governance changes or amendment of charter/bylaws concurrent with contract execution suggests potential changes to share structure, board composition, or shareholder rights. Item 8.01 (Other) classification may obscure the nature of Item 1.03 or Item 4.01 materiality.
2026-07-20 8-K	Unregistered Sales of Equity Securities (Item 1.03) and amendment to organizational documents (Item 3.01). · filing Company conducted private placement or issued restricted stock/options to insiders or strategic partners without public offering. Coupled with Item 3.01 amendments, this may signal dilution to existing shareholders or shift in ownership structure.
2026-06-23 8-K	Financial statements or exhibits filed (Item 9.01) in connection with material transaction. · filing Supporting documentation for the June 23 material agreement; investors should request the full agreement text and pro forma financials to understand deal economics and impact on balance sheet.
2026-05-14 8-K	Costs Associated with Exit or Disposal Activities (Item 2.02) and material cost/charges disclosed. · filing Severance, facility closure, or business line discontinuation announced. May indicate pipeline setbacks, failed collaboration, or asset write-downs. Magnitude of Item 2.02 costs should be evaluated against quarterly earnings.
2026-04-29 8-K	Amendment to organizational documents filed (Item 3.01) but reported under Item 8.01 (Other). · filing Potential governance or charter amendment not explicitly flagged. Misclassification under 8.01 instead of 3.01 may indicate urgency or lack of materiality threshold disclosure. Investors should review full text for bylaw or shareholder agreement changes.

Financing activity

No registered ATM shelf offerings or public capital raises are documented in the 8-K filings. Item 1.03 (unregistered sales) on July 20, 2026 indicates a private placement or restricted equity transaction; Item 2.05 (direct financial obligations) on June 23 and May 14 suggests debt or contingent liabilities rather than equity financing. No shelf registration size or capacity disclosed.

Risk signals

Item 2.02 and Item 2.05 filings (May 14, June 23, 2026) indicate material exit/disposal costs and new debt or financial obligations; full quantum and terms not disclosed in 8-K headers alone—10-Q and 10-K analysis required to assess liquidity impact.
Item 1.03 unregistered equity sale on July 20, 2026 coupled with Item 3.01 organizational amendments suggests potential dilution or change in control; absence of definitive agreement text prevents assessment of dilution magnitude and investor protection.
Discrepancy in Item 3.01 classification on April 29, 2026 (filed under 8.01 instead of 3.01) and July 1, 2026 (buried in 8.01) raises questions about governance rigor and potential non-disclosure of material charter/bylaw changes.
Material definitive agreement on June 23, 2026 (Item 1.01) lacking public detail; investors should obtain full agreement from SEC EDGAR or company investor relations to evaluate counterparty creditworthiness, termination conditions, and revenue/milestone recognition.
Concentration of significant events in June–July 2026 (material agreement, workforce reduction, equity issuance, debt creation) within a 28-day window suggests rapid strategic repositioning; execution risk and market execution risk are elevated.
No evidence of equity compensation cancellation, buyback program suspension, or management retention packages; if material officers departed or were terminated, undisclosed equity awards may represent future dilution or accounting charges.

Bottom line

Sangamo Therapeutics underwent significant operational and financial restructuring in mid-2026, marked by a material agreement, workforce reduction, unregistered equity issuance, and new liabilities—all compressed into a six-week window. Given the filing evidence, an investor should obtain full copies of the June 23, 2026 material agreement and any private placement term sheet from Item 1.03 to assess the magnitude of dilution, debt burden, and strategic rationale; concurrently, review the company's 10-Q and 10-K for cash burn rate, covenant compliance, and product pipeline viability, as these 8-K summaries lack sufficient detail to evaluate financial sustainability or shareholder value creation.

View this report online